Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial - Malmstrom, A; Gronberg, B H; Marosi, C (Lancet Oncol, 2012)
et al.